Tagged with Ascentage

China China Pharma Roundup: Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?

China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent. Sinopharm Tops Ranking of…

Hong Kong Biotech IPOs since Listing Reform in April 2018

Hong Kong Hong Kong Biotech IPOs since Listing Reform in April 2018

Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…

China Pharma News Roundup May 11th 2020

China China Pharma News Roundup May 11th 2020

China Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan drug status for its leukaemia candidate. Hong Kong IPOs Pick Up the Pace as China Restarts https://www.bloombergquint.com/onweb/hong-kong-ipos-pick-up-the-pace-as-china-restarts-ecm-watch Initial public…

China: A New Decade

China China: A New Decade

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Chinese Oncology Biotechs to Watch

China Chinese Oncology Biotechs to Watch

China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…

Dajun Yang – Chairman, Executive Director & CEO, Ascentage Pharma, China

China Dajun Yang – Chairman, Executive Director & CEO, Ascentage Pharma, China

China Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio of innovative therapeutics focusing on protein-protein interactions (PPIs); and their global strategy to become an international, world-class biotech company. …

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page